
JMP Securities
http://www.jmpsecurities.com/index.htmlJMP Securities provides investment banking services, institutional brokerage, and equity research to public and private growth companies. Equity research is the backbone of the firm and the industries the firm covers are: Business Services, Financial Services, Real Estate, Consumer, Healthcare, and Technology. The firm is headquartered in San Francisco, CA and is a subsidiary of JMP Group (NYSE: JMP).
View Older Stories
-
BioCryst to Present at Upcoming Investor Conferences
-
JMP Securities Maintains Bullish View on BioCryst Pharma (BCRX) After Orladeyo Approved in the EU
-
BioCryst to Present at JMP Securities Hematology Summit
-
BioCryst Pharma (BCRX) PT Raised to 'Street High' $16 at JMP Securities
-
BioCryst Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Completion of Public Offering of Common Stock and Pre-Funded Warrants
-
BioCryst Pharma (BCRX) Prices 18.7M Share Common Offering at $4.50/Sh; Announces Pricing of Pre-Funded Warrants Offering
-
BioCryst Prices Public Offering of Common Stock and Pre-Funded Warrants
-
BioCryst Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Completion of Public Offering of Common Stock
-
BioCryst Pharma (BCRX) Prices 37.93M Share Common Offering at $1.45/Sh
-
BioCryst Prices Public Offering of Common Stock
-
BioCryst Pharma (BCRX) Commences $55M Public Offering of Common Stock
-
BioCryst Commences Public Offering of Common Stock
-
BioCryst to Present at Upcoming Investor Conferences
-
BioCryst Pharma (BCRX) PT Raised to $18 at JMP Securities
-
BioCryst Pharma (BCRX) PT Raised to $16 at JMP Securities
-
BioCryst Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Completion of Public Offering of Common Stock
-
BioCryst Pharma (BCRX) Prices 9.09M Shares Common Offering at $5.50/Sh
-
BioCryst Pharmaceuticals Prices Public Offering of Common Stock
-
BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at the JMP Securities Life Sciences Conference
-
BioCryst to Present at the JMP Securities 2017 Life Sciences Conference
-
BioCryst Pharma (BCRX) Prices 5.29M Share Offering at $8.50
-
BioCryst Pharmaceuticals Prices Public Offering of Common Stock
-
JMP Securities Upgrades BioCryst Pharma (BCRX) to Market Outperform
-
JMP Securities Downgrades BioCryst Pharma (BCRX) to Market Perform
-
BioCryst to Present at Two Upcoming Investor Conferences
-
BioCryst to Present at the JMP Securities Life Sciences Conference
-
BioCryst to Present at the JMP Securities Life Sciences Conference
-
BioCryst Announces Exercise of Over-Allotment Option and Completion of Public Offering
-
BioCryst to Present at Two Upcoming Investor Conferences
-
BioCryst Pharmaceuticals Prices Public Offering of Common Stock
-
Notable Analyst Rating Changes 01/28: (FTNT) (MLM) (MT) Upgraded; BHI) (BCRX) (HIMX) Downgraded
-
BioCryst Pharma (BCRX) Target Raised to $8 at JMP
-
BioCryst (BCRX) Underwriters Fully Exercise Over Allotment
-
Streetinsider.com Pre-Open Movers 07/31: (TSRX) (QCOR) (AEGR) Higher; (JIVE) (RVBD) (BGFV) Lower (more...)
-
BioCryst (BCRX) Announces Up to $20M Common Offering
-
Unusual 11 Mid-Day Movers 07/19: (OXGN) (HGSH) (USU) Higher; (AMD) (OCRX) (ISRG) Lower
-
Notable Analyst Rating Changes 07/19: (BBRY) (BCRX) (STX) Upgraded; (MSFT) (AMD) (ISRG) Downgraded
-
Streetinsider.com Pre-Open Movers 07/19: (OXGN) (ASTX) (SWKS) Higher; (ISRG) (MSFT) (CYH) Lower (more...)
-
JMP Securities Upgrades BioCryst Pharma (BCRX) to Market Outperform
-
BioCryst Pharma (BCRX) Rally Overdone, Says Analyst
-
JMP Securities Downgrades BioCryst Pharma (BCRX) to Market Perform
-
Positives Seen On BioCryst (BCRX) After Peramivir Granted Priority Review In Japan
-
BioCryst Pharma (BCRX) Priced 5M Common Offering at $9.75/Share
-
BioCryst Pharma (BCRX) Files 5M Common Stock Shelf